Today, the health minister of Haryana, Anil Vij, announced on his twitter page that clinical trials to fight Covid-19 with Covaxin have started at the Post Graduate Institute of Medical Sciences, Rohtak. This was one of the 12 locations selected to execute the trails by the ICMR. He said three subjects who were enrolled went for the trails today, and they have tolerated the vaccine well without adverse effects.
Development to Trials
PGIMS started enrolling subjects for clinical trails almost 10 days back. Around a hundred individuals from Haryana registered to be a part of the trial. PGIMS Rohtak officials said that 22 of these volunteers had been screened for their medical history, and then three of them were finally selected for the first trial.
Dr. Dhruv Chaudhary, who is a part of a three-member team leading the clinical trials at PGIMS, Rohtak, said, another 14 people were screened on Thursday and they were waiting for their biochemical reports.
Last week, it was reported that the Indian Council for Medical Research (ICMR), in joint partnership with Bharat Biotech has developed India’s very own COVID-19 vaccine named Covaxin. The encouraging news is that the vaccine passed the animal trial successfully and has now entered the human trial phase.
What is Covaxin?
Covaxin is mainly an indigenous Covid-19 vaccine, made from dead particles of the SARS-CoV-2, after disabling them from infecting or replicating. The body will produce antibodies to fight the foreign body when the vaccine is injected. And it is expected to be able to handle the live virus just as vaccines usually work.
The vaccine was developed by Bharat Biotech and the ICMR’s National Institute of Virology, Pune. The Drug Controller General of India gave permission to them to proceed with two phases of human clinical trials.
Read more latest news:
